RenovoRx Inc expected to post a loss of 8 cents a share - Earnings Preview

RenovoRx

13/05/2025 21:28

RenovoRx Inc RNXT.OQ RNXT.O is expected to show a rise in quarterly revenue when it reports  results on May 15 for the period ending March 31 2025

The Mountain View California-based  company is expected to report revenue of $225 thousand, according to the mean estimate from 2 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for RenovoRx Inc is for a loss of 8 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 6.5% in the last three months. ‚Äč

Wall Street's median 12-month price target for RenovoRx Inc is $4.00‚Äč, above‚Äč its last closing price of $1.06. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.12
-0.11
-0.13
Missed
-18.2
Sep. 30 2024
-0.12
-0.12
-0.10
Beat
16.7
Jun. 30 2024
-0.10
-0.10
-0.10
Met
0‚Äč
Mar. 31 2024
-0.13
-0.14
-0.07
Beat
51.7
‚Äč‚ÄčDec. 31 2023
-0.30
-0.30
-0.31
Missed
-2.2
Sep. 30 2023
-0.30
-0.30
-0.13
Beat
56.7‚Äč
Jun. 30 2023
-0.25
-0.25
-0.31
Missed
-24
Mar. 31 2023
-0.25
-0.25
-0.36
Missed
-44

This summary was machine generated May 13 at 20:28 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)